Pall, Cytiva & the Bioprocessing Manufacturing Process
Former VP of Sales at Pall Corp
inpractise.com/articles/pall-cytiva-and-the-bioprocessing-manufacturing-process
Former VP of Sales at Pall Corp
Interview Transcript
This is a snippet of the transcript, sign up to read more.
According to this data, in 2018 Pall made one billion in biopharma revenue, of which $300 million was from single-use technologies.
The impact largely depends on how many processes transition to continuous processing. The advent of continuous processing won't affect their core business that they've built over the years, as most processes won't shift to continuous processing. It's probably going to be more about how it affects the growth rate in the future. I'd need to do some calculations to think this through a bit more. I'm currently working with a few companies on continuous processing for vaccines. I can get some insight from a colleague who has experience with continuous processes on the API side. He's worked with processes that Vertex uses for some of their solid dosage. I'll get back to you on this, as it requires more than just back-of-the-napkin math.
This is a snippet of the transcript, sign up to read more.
How did you get your products specified early when you were at Pall?
It's about developing relationships with companies and giving them access to your engineers and scientists to work on the process. When I was doing sales for Millipore, this approach was key to my success. I provided an extra set of hands that the company didn't have to pay for.
This is a snippet of the transcript, sign up to read more.
Related Content
Danaher, Sartorius, & an Overview of The Bioprocessing Environment
Former VP of Sales at Pall Corp
Danaher: Cytiva's Bioprocessing Filtration Portfolio
Former VP of Sales at Pall Corp
Sartorius Stedim Biotech: Post-Covid Sourcing Strategy & Price Competition
Former Account Management Executive at Sartorius Stedim Biotech
Danaher & the Bioprocessing FDA Approval Process
Former Head of Sales, GE Life Sciences
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.